Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities.

Dhagat U, Hercus TR, Broughton SE, Nero TL, Cheung Tung Shing KS, Barry EF, Thomson CA, Bryson S, Pai EF, McClure BJ, Schrader JW, Lopez AF, Parker MW.

MAbs. 2018 Oct;10(7):1018-1029. doi: 10.1080/19420862.2018.1494107. Epub 2018 Sep 12.


Biological Evaluation and X-ray Co-crystal Structures of Cyclohexylpyrrolidine Ligands for Trypanothione Reductase, an Enzyme from the Redox Metabolism of Trypanosoma.

De Gasparo R, Brodbeck-Persch E, Bryson S, Hentzen NB, Kaiser M, Pai EF, Krauth-Siegel RL, Diederich F.

ChemMedChem. 2018 May 8;13(9):957-967. doi: 10.1002/cmdc.201800067. Epub 2018 Apr 6.


Structures of Preferred Human IgV Genes-Based Protective Antibodies Identify How Conserved Residues Contact Diverse Antigens and Assign Source of Specificity to CDR3 Loop Variation.

Bryson S, Thomson CA, Risnes LF, Dasgupta S, Smith K, Schrader JW, Pai EF.

J Immunol. 2016 Jun 1;196(11):4723-30. doi: 10.4049/jimmunol.1402890. Epub 2016 Apr 29.


Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity.

Goodreid JD, Janetzko J, Santa Maria JP Jr, Wong KS, Leung E, Eger BT, Bryson S, Pai EF, Gray-Owen SD, Walker S, Houry WA, Batey RA.

J Med Chem. 2016 Jan 28;59(2):624-46. doi: 10.1021/acs.jmedchem.5b01451. Epub 2016 Jan 12.


Binding to large enzyme pockets: small-molecule inhibitors of trypanothione reductase.

Persch E, Bryson S, Todoroff NK, Eberle C, Thelemann J, Dirdjaja N, Kaiser M, Weber M, Derbani H, Brun R, Schneider G, Pai EF, Krauth-Siegel RL, Diederich F.

ChemMedChem. 2014 Aug;9(8):1880-91. doi: 10.1002/cmdc.201402032. Epub 2014 Apr 30.


Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design.

Serrano S, Araujo A, Apellániz B, Bryson S, Carravilla P, de la Arada I, Huarte N, Rujas E, Pai EF, Arrondo JL, Domene C, Jiménez MA, Nieva JL.

J Biol Chem. 2014 Mar 7;289(10):6565-80. doi: 10.1074/jbc.M113.527747. Epub 2014 Jan 15.


Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope.

Azoitei ML, Ban YE, Julien JP, Bryson S, Schroeter A, Kalyuzhniy O, Porter JR, Adachi Y, Baker D, Pai EF, Schief WR.

J Mol Biol. 2012 Jan 6;415(1):175-92. doi: 10.1016/j.jmb.2011.10.003. Epub 2011 Oct 31.


Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.

Bryson S, Julien JP, Hynes RC, Pai EF.

J Virol. 2009 Nov;83(22):11862-75. doi: 10.1128/JVI.01604-09. Epub 2009 Sep 9.


Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.

Julien JP, Bryson S, Nieva JL, Pai EF.

J Mol Biol. 2008 Dec 12;384(2):377-92. doi: 10.1016/j.jmb.2008.09.024. Epub 2008 Sep 18.


Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus.

Thomson CA, Bryson S, McLean GR, Creagh AL, Pai EF, Schrader JW.

EMBO J. 2008 Oct 8;27(19):2592-602. doi: 10.1038/emboj.2008.179. Epub 2008 Sep 4.


Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.

Bryson S, Julien JP, Isenman DE, Kunert R, Katinger H, Pai EF.

J Mol Biol. 2008 Oct 17;382(4):910-9. doi: 10.1016/j.jmb.2008.07.057. Epub 2008 Jul 27.


A point mutation in the Ch3 domain of human IgG3 inhibits antibody secretion without affecting antigen specificity.

McLean GR, Torres M, Trotter B, Noseda M, Bryson S, Pai EF, Schrader JW, Casadevall A.

Mol Immunol. 2005 May;42(9):1111-9. Epub 2005 Jan 4.


Supplemental Content

Loading ...
Support Center